07.01.2014 • NewsBiosucciniumBiotechnologyDSM

Marcel Lubben Named President of Reverdia

Reverdia has appointed Marcel Lubben as its new president
Reverdia has appointed Marcel Lubben as its new president

Reverdia, a joint venture between DSM and Roquette Frères, has appointed Marcel Lubben as its new president. Lubben replaces General Manager Will van den Tweel, who led the start-up of Reverdia. Van den Tweel drove the joint collaboration between Roquette and DSM on Biosuccinium and was one of the founders of DSM's innovation initiatives into industrial biotechnology.

Lubben joined DSM in 1994. He held positions in Research, Business Development and Marketing & Sales in DSM Pharma Chemicals and DSM Biologics before transitioning into the industrial biotechnology sector. In 2009, he was appointed Managing Director Licensing for DSM and became Managing Director Venturing & Licensing in 2011. In 2012 he became vice president Bio-based Chemicals & Materials, and he served as a member of the Reverdia board from mid-2012 until the end of 2013.

Company

Reverdia

Urmonderbaan 20H
6167 RD Geleen

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read